StockNews.com Initiates Coverage on VolitionRx (NYSE:VNRX)

Equities research analysts at StockNews.com began coverage on shares of VolitionRx (NYSE:VNRX) in a report released on Tuesday. The brokerage set a “sell” rating on the stock.

Other equities analysts have also issued reports about the company. D. Boral Capital reiterated a “buy” rating and set a $5.00 price objective on shares of VolitionRx in a research report on Tuesday, December 10th. Benchmark reiterated a “hold” rating on shares of VolitionRx in a research report on Friday, November 22nd.

VolitionRx Stock Down 5.0 %

VNRX opened at $0.64 on Tuesday. The business’s fifty day simple moving average is $0.65 and its 200 day simple moving average is $0.66. VolitionRx has a 52 week low of $0.43 and a 52 week high of $1.23. The stock has a market cap of $59.20 million, a PE ratio of -1.77 and a beta of 1.20.

Insiders Place Their Bets

In related news, Director Guy Archibald Innes acquired 174,764 shares of the firm’s stock in a transaction on Monday, December 9th. The stock was acquired at an average cost of $0.57 per share, for a total transaction of $99,615.48. Following the acquisition, the director now owns 617,085 shares of the company’s stock, valued at $351,738.45. This trade represents a 39.51 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Cameron John Reynolds bought 139,811 shares of the company’s stock in a transaction dated Monday, December 9th. The stock was bought at an average cost of $0.57 per share, with a total value of $79,692.27. Following the completion of the transaction, the chief executive officer now owns 2,117,404 shares in the company, valued at approximately $1,206,920.28. This trade represents a 7.07 % increase in their position. The disclosure for this purchase can be found here. Insiders have bought a total of 358,266 shares of company stock valued at $204,212 in the last quarter. Insiders own 12.80% of the company’s stock.

Hedge Funds Weigh In On VolitionRx

A hedge fund recently raised its stake in VolitionRx stock. Ground Swell Capital LLC raised its position in shares of VolitionRx Limited (NYSE:VNRX) by 78.8% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 45,959 shares of the company’s stock after buying an additional 20,249 shares during the quarter. Ground Swell Capital LLC’s holdings in VolitionRx were worth $28,000 at the end of the most recent quarter. 8.09% of the stock is owned by institutional investors.

VolitionRx Company Profile

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.